RUNX2 and melanoma: Therefore, we used FAK mRNA as a control for RUNX2 loss of activity and confirmed a reduction of FAK expression in melanoma cells transfected with the selected Adaptors RA2 and RA5 for C8161 cells, and RA2 and RA4 for 1205LU cells (Figure 3C).